SEE INSIDE - Pittsburgh Tissue Engineering Initiative

Preliminary Program – For full details of the Scientific Sessions check: www.regenerate-online.com
WEDNESDAY - APRIL 26 continued
TRACK
TRACK
CHAIR
Cell Sourcing II
Johnny Huard, PhD
McGowan Institute for Regenerative Medicine
Tissue Engineering & Regenerative
Medicine in the Clinic (Part 1)
Stephen Badylak, DVM, MD, PhD
McGowan Institute for Regenerative Medicine
Cell Tracking
Dan Gazit, PhD, DMD
The Hebrew University of Jerusalem
6
TRACK
DESCRIPTION
TRACK
Presentations will include novel models for
cell manipulation including mechanical
stimulation and transfection. Chemical means
to induce differentiation and de-differentiation
will be discussed. Optimization of methods for
isolation and induction of cells for research
and clinical application will be presented.
Embryonic Stem Cells I
The subject matter of this session focuses upon the
clinical translation of regenerative medicine concepts
from the benchtop to the bedside and patient care. The
talks cover aspects of regulatory requirements, academicindustry
collaborations, third party reimbursement issues,
and important clinical considerations for moving
regenerative medicine into the clinic.
Tissue Engineering & Regenerative
Medicine in the Clinic (Part 2)
Cell tracking could be a crucial issue in cell therapy and tissue
engineering. Either in a systemic or local approach of cell
implantation, tracking and monitoring the therapeutic cells is
mandatory in order to determine:
•Cell survival
•Biodistribution
•Cell function in tissue/organ repair (i.e. stem cell
differentiation).
•Cell homing and engraftment.
Conventional methods of cell tracking included invasive methods
that required the sacrifice of the experimental model avoiding
the possibility of longitudinal, real-time monitoring of cells in vivo.
Current, state-of-the-art technologies utilize genetic engineering,
bioluminescence, fluorescence, nanotechnology and intra vital
microscopy in order to provide non invasive, quantitative and longitudinal
tracking of cells in vivo. There is no doubt that by better
means of cell tracking in vivo, the field of tissue engineering
would be able to better understand regeneration processes and
to optimize cell-based approaches for tissue repair.
Advances in Cell Culture Media
TRACK
CHAIR
Todd McDevitt, PhD
Georgia Institute of Technology and Emory University
Dong-Wook Kim, PhD
Yonsei University College of Medicine
Stephen Badylak, DVM, MD, PhD
McGowan Institute for Regenerative Medicine
David Grainger, PhD
Colorado State University
TRACK
DESCRIPTION
Embryonic stem (ES) cells may serve as a
pluripotent cell source for the treatment of a
number of degenerative cellular diseases. This
session will highlight recent advances in the
derivation, cultivation and differentiation
methods for ES cells, as well as the
development of novel therapeutic applications
of ES cells and stem cell-derived products.
The subject matter of this session focuses upon the
clinical translation of regenerative medicine concepts
from the benchtop to the bedside and patient care. The
talks cover aspects of regulatory requirements, academicindustry
collaborations, third party reimbursement issues,
and important clinical considerations for moving
regenerative medicine into the clinic.
Various deliberate and inadvertent cell culture conditions are
becoming increasingly recognized for important influences
on cells in culture. Different media, different serum sources,
serum-free additives, and specific growth factors and hormones
are soluble variables; hydrodynamic shear, oscillatory
changes, and other fluid stimuli are another source of vari -
ables. Full appreciation of these conditions is important to
control cell phenotypic stability and regenerative destiny in
cultures and bioreactors. This session provides a forum for
presenting and discussing the latest thinking regarding such
influences on secondary, primary and stem cell lineages.
TRACK
Cell-Based Sensing
Pre-clinical Studies and Clinical Success:
Guiding Principles (Panel Session)
Cell Integration into Natural & Synthetic Matrices
TRACK
CHAIR
William Reichert, PhD
Duke University
Anne Plant, PhD
National Institute of Standards and Technology
Kiki Hellman, PhD
The Hellman Group LLC
Arnold Caplan, PhD
Case Western Reserve
TRACK
DESCRIPTION
This session on cell-based biosensors examines
analytical systems that employ or take
advantage of detection and transduction
schemes intrinsic to native cells or engineered
into cells modified for analytical purposes.
Particular interest is placed on
approaches that are implementable in a high
throughput format or that are amenable to
combinatorial assay.
The panel focuses on discussions and development of
generic considerations for pre-clinical and clinical studies
that lead to a successful therapy. Special attention is
given to preclinical studies as key determinants for
clinical success with focus on: clinical trial design;
selection of patient profiles, i.e., inclusion/exclusion
criteria; and determination of safety and effectiveness
criteria and assessment measures.
The principles of tissue formation and properties of
natural materials can be merged to provide composite
constructs used for tissue engineered regeneration of
various tissues. Key issues addressed involve the use of
the appropriate cells, in the proper numbers and in the
optimal formulation of natural materials to organize
tissue engineered regeneration.
BioBlast - J.J. Collins, MD, Center for BioDynamics and the Development of Biomedical Engineering, Boston University